85 related articles for article (PubMed ID: 23884369)
21. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
[TBL] [Abstract][Full Text] [Related]
22. Frequent PIK3CA activating mutations in nipple adenomas.
Liau JY; Lee YH; Tsai JH; Yuan CT; Chu CY; Hong JB; Sheen YS
Histopathology; 2017 Jan; 70(2):195-202. PubMed ID: 27441415
[TBL] [Abstract][Full Text] [Related]
23. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
24. [Roles of Aurora-A in tumorigenesis and prognosis of breast cancer].
Xia LP; Zhou FF; Yang MT; Liu Q
Ai Zheng; 2009 Jun; 28(6):668-72. PubMed ID: 19635209
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
26. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
[TBL] [Abstract][Full Text] [Related]
27. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
Katsios C; Ziogas DE; Roukos DH
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
[No Abstract] [Full Text] [Related]
28. Molecular profiles of benign and (pre)malignant endometrial lesions.
van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG
Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752
[TBL] [Abstract][Full Text] [Related]
29. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
[TBL] [Abstract][Full Text] [Related]
30. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
31. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.
Turturro SB; Najor MS; Ruby CE; Cobleigh MA; Abukhdeir AM
Breast Cancer Res Treat; 2016 Feb; 156(1):33-43. PubMed ID: 26915040
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
[TBL] [Abstract][Full Text] [Related]
33. Gene expression signatures of breast cancer stem and progenitor cells do not exhibit features of Warburg metabolism.
Gordon N; Skinner AM; Pommier RF; Schillace RV; O'Neill S; Peckham JL; Muller P; Condron ME; Donovan C; Naik A; Hansen J; Pommier SJ
Stem Cell Res Ther; 2015 Aug; 6(1):157. PubMed ID: 26316122
[TBL] [Abstract][Full Text] [Related]
34. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
35. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
36. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
[TBL] [Abstract][Full Text] [Related]
38. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
39. Acta Oncologica and a new generation of scientists in oncology.
Glimelius B; Johansen C; Muren LP; Nilbert M
Acta Oncol; 2014 Jul; 53(7):849-51. PubMed ID: 24954366
[No Abstract] [Full Text] [Related]
40. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF
Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
